TENELIGLIPTIN HYDROBROMIDE HYDRATE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C22H30N6OS.5BrH.H2O
Molecular Weight	1275.731
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TENELIGLIPTIN HYDROBROMIDE HYDRATE

Structure Search

SMILES

O.Br.Br.Br.Br.Br.[H][C@]1(CN[C@@]([H])(C1)C(=O)N2CCSC2)N3CCN(CC3)C4=CC(C)=NN4C5=CC=CC=C5.[H][C@]6(CN[C@@]([H])(C6)C(=O)N7CCSC7)N8CCN(CC8)C9=CC(C)=NN9C%10=CC=CC=C%10

InChI

InChIKey=NQPRXLXVOBOTGT-KSLCDFCZSA-N

InChI=1S/2C22H30N6OS.5BrH.H2O/c2*1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27;;;;;;/h2*2-6,13,19-20,23H,7-12,14-16H2,1H3;5*1H;1H2/t2*19-,20-;;;;;;/m00....../s1

HIDE SMILES / InChI

Molecular Formula	BrH
Molecular Weight	80.912
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C22H30N6OS
Molecular Weight	426.578
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23671395
Curator's Comment: description was created based on several sources, including https://www.pmda.go.jp/files/000153594.pdf

Teneligliptin is a DPP IV inhibitor which was developed by Mitsubishi Tanabe Pharma and now is used for the treatment of type 2 diabetes mellitus in Asia under the name Tenelia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dipeptidyl peptidase IV 37 Target ID: CHEMBL284 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23671395	Inhibitor 8297		0.889 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 259 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23671395	Primary		Approved 8429	TENELIA Approved Use Type 2 diabetes mellitus. Launch Date 1.33548474E12

PubMed

Title	Date	PubMed
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.	2012 Oct 1	22959556
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.	2013	23671395
Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus.	2013 Nov 27	24843712
Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.	2013 Sep	23464664
Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes.	2014 Aug	24883155
Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.	2014 Dec	25144424
Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.	2015	25252844
Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.	2015 Sep	26224337
Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study.	2016	27832184

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage is 20 mg of teneligliptin administered orally once daily. If efficacy is insufficient, the dose may be increased up to 40 mg once daily while closely monitoring the clinical course.

Route of Administration: Oral

In Vitro Use Guide

Human umbilical vein endothelial cells were cultured under normal (5 mmol/L) or high glucose level (25 mmol/L) during 21 days, or at high glucose during 14 days followed by 7 days at normal glucose, to reproduce the high-metabolic memory state. At this time, different concentrations of teneligliptin (0.1, 1.0 and 3.0 umol/L) were added to cells. Teneligliptin was shown to protect human umbilical vein endothelial cells from oxidative stress.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:14:35 UTC 2023` Edited by `admin` on `Fri Dec 15 19:14:35 UTC 2023`
Record UNII	15S4OCS6SS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TENELIGLIPTIN HYDROBROMIDE HYDRATE

Common Name

English

Teneligliptin hydrobromide hydrate [WHO-DD]

Common Name

English

METHANONE, ((2S,4S)-4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)-1-PIPERAZINYL)-2-PYRROLIDINYL)-3-THIAZOLIDINYL-, HYDROBROMIDE, (2:5) , HYDRATE

Systematic Name

English

Code System Code Type Description

PUBCHEM

53297474